Search results
Test Id : AB2GP. Evaluating patients with suspected antiphospholipid syndrome by identification of beta-2 glycoprotein 1 IgA antibodies. Evaluating patients at-risk for antiphospholipid syndrome (APS) who are negative for criteria APS tests.
- Download
5. Lozier J, Takahashi N, Putnam F W: Complete amino acid...
- PDF
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- File Definition
Beta-2 Glycoprotein 1 Antibodies, IgA, Serum; Test ID:...
- Overview
Evaluating patients with suspected antiphospholipid syndrome...
- Download
Evaluating patients with suspected antiphospholipid syndrome by identification of beta-2 glycoprotein 1 IgG antibodies. First-line test when antiphospholipid syndrome is strongly suspected, in conjunction with cardiolipin antibodies (IgG and IgM) and lupus anticoagulant testing.
Evaluating patients with suspected antiphospholipid syndrome by identification of beta-2 glycoprotein 1 IgM and IgG antibodies . First-line test when antiphospholipid syndrome is strongly suspected in conjunction with cardiolipin antibodies (IgG and IgM) and lupus anticoagulant testing
Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that possess the dual capability to up and down regulate the complement and coagulation systems depending upon external stimulus.
Anti-beta 2 glycoprotein 1 (anti-β 2 GP1) antibodies are commonly found in patients with autoimmune diseases such as the antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Their presence is highly associated with increased risk of vascular thrombosis and/or recurrent pregnancy-related complications.
These are lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta-2 glycoprotein I antibodies (anti-B2GPI). This review will focus on anti-B2PI and their role in APS in terms of their relationship to the putative pathogenesis of the disorder and their clinical associations.
Immune thrombocytopenia (ITP) assumes a chronic course in most affected adults. 1 The goal of treatment is to achieve and maintain a hemostatic platelet count (≥30×10 3 /μL for most patients and situations) while minimizing treatment-related morbidity.
